CGON saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 24, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 27 instances where the indicator turned negative. In 23 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 85%.
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGON as a result. In 37 of 48 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
CGON moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CGON crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for CGON entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for CGON's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in 115 of 143 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
CGON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.995) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Aroon Indicator for MLTX entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 123 similar instances where the Aroon Indicator formed such a pattern. In 101 of the 123 cases the stock moved lower. This puts the odds of a downward move at 82%.
The Moving Average Convergence Divergence Histogram (MACD) for MLTX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 39 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
The 50-day moving average for MLTX moved below the 200-day moving average on September 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +7.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in 256 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MLTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.298) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MLTX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 65 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CGON | MLTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 77% | N/A |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 75% | 2 days ago 73% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 73% |
| Advances ODDS (%) | 9 days ago 80% | 26 days ago 84% |
| Declines ODDS (%) | 4 days ago 77% | 4 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGON’s FA Score shows that 0 FA rating(s) are green while MLTX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGON’s TA Score shows that 4 TA indicator(s) are bullish while MLTX’s TA Score has 4 bullish TA indicator(s).
CGON (@Biotechnology) experienced а -6.22% price change this week, while MLTX (@Biotechnology) price change was -11.74% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
CGON is expected to report earnings on Nov 12, 2026.
MLTX is expected to report earnings on Nov 17, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GGLS | 58.76 | 1.46 | +2.54% |
| Direxion Daily GOOGL Bear 1X ETF (GGLS) | |||
| GDXJ | 109.91 | 0.30 | +0.27% |
| VanEck Junior Gold Miners ETF (GDXJ) | |||
| USEW | 56.17 | N/A | N/A |
| Cambria US EW ETF (USEW) | |||
| NCPB | 23.98 | N/A | -0.01% |
| Nuveen Core Plus Bond ETF (NCPB) | |||
| LONZ | 48.76 | -0.01 | -0.03% |
| PIMCO Senior Loan Active Exchange-Traded Fund (LONZ) | |||
A.I.dvisor indicates that over the last year, CGON has been loosely correlated with MLTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then MLTX could also see price increases.
| Ticker / NAME | Correlation To CGON | 1D Price Change % | ||
|---|---|---|---|---|
| CGON | 100% | -3.25% | ||
| MLTX - CGON | 46% Loosely correlated | -6.92% | ||
| IDYA - CGON | 42% Loosely correlated | -2.95% | ||
| BCAX - CGON | 42% Loosely correlated | -4.77% | ||
| SRRK - CGON | 42% Loosely correlated | -1.82% | ||
| ORKA - CGON | 41% Loosely correlated | -2.63% | ||
More | ||||